Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Preferred Stock Liabilities (2019 - 2020)

C4 Therapeutics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $256.5 million for Q3 2020.

  • For Q3 2020, Preferred Stock Liabilities rose 133.21% year-over-year to $256.5 million; the TTM value through Sep 2020 reached $256.5 million, up 133.21%, while the annual FY2019 figure was $111.0 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $256.5 million in Q3 2020 per CCCC's latest filing, up from $110.0 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $256.5 million in Q3 2020 to a low of $110.0 million in Q3 2019.